Dapivelin vaginal ring, a new option for preventing AIDS

The World Health Organization (WHO) today recommended that dapivellin vaginal rings (DPV-VR) be used as a prevention strategy for patients at significant risk of infection as part of a joint prevention approach.
DPV-VR can reduce the risk of HIV infection.
in order to use the vaginal ring correctly, you must wear it in the vagina for 28 days before replacing it with a new vaginal ring.
vaginal rings are made of silicone resin and are easy to bend and insert.
the ring works by slowly releasing the antiretroviral drug dapivirine from the vaginal ring into the vagina within 28 days.
phase III randomized controlled trials found that the use of DVV-VR reduced a woman's risk of HIV infection and had good long-term tolerance.
use of DVV-VR can reduce a woman's risk of HIV infection by 27%-35%.
the results of the open label extension study showed that women who always used DVV-VR had a higher risk reduction rate of HIV.
DPV-VR can be used with oral PrEP (pre-exposure prevention) as an option for women who do not wish or are unable to take oral tablets daily.
despite the fact that contraceptive rings have been around for years, DVV-VR was the first to prevent HIV.